A  ||| S:0 E:2 ||| DT
multi-factor  ||| S:2 E:15 ||| JJ
model  ||| S:15 E:21 ||| NN
for  ||| S:21 E:25 ||| IN
caspase  ||| S:25 E:33 ||| JJ
degradome  ||| S:33 E:43 ||| JJ
prediction  ||| S:43 E:54 ||| NN
Caspases  ||| S:54 E:63 ||| NNS
belong  ||| S:63 E:70 ||| VBP
to  ||| S:70 E:73 ||| TO
a  ||| S:73 E:75 ||| DT
class  ||| S:75 E:81 ||| NN
of  ||| S:81 E:84 ||| IN
cysteine  ||| S:84 E:93 ||| JJ
proteases  ||| S:93 E:103 ||| NN
which  ||| S:103 E:109 ||| WDT
function  ||| S:109 E:118 ||| VBP
as  ||| S:118 E:121 ||| RB
critical  ||| S:121 E:130 ||| JJ
effectors  ||| S:130 E:140 ||| NN
in  ||| S:140 E:143 ||| IN
cellular  ||| S:143 E:152 ||| JJ
processes  ||| S:152 E:162 ||| NNS
such  ||| S:162 E:167 ||| JJ
as  ||| S:167 E:170 ||| IN
apoptosis  ||| S:170 E:180 ||| NN
and  ||| S:180 E:184 ||| CC
inflammation  ||| S:184 E:197 ||| NN
by  ||| S:197 E:200 ||| IN
cleaving  ||| S:200 E:209 ||| JJ
substrates  ||| S:209 E:220 ||| NNS
immediately  ||| S:220 E:232 ||| RB
after  ||| S:232 E:238 ||| IN
unique  ||| S:238 E:245 ||| JJ
tetrapeptide  ||| S:245 E:258 ||| JJ
sites ||| S:258 E:263 ||| NNS
.  ||| S:263 E:265 ||| .
With  ||| S:265 E:270 ||| IN
hundreds  ||| S:270 E:279 ||| NNS
of  ||| S:279 E:282 ||| IN
reported  ||| S:282 E:291 ||| JJ
substrates  ||| S:291 E:302 ||| NN
and  ||| S:302 E:306 ||| CC
many  ||| S:306 E:311 ||| JJ
more  ||| S:311 E:316 ||| RBR
expected  ||| S:316 E:325 ||| VBN
to  ||| S:325 E:328 ||| TO
be  ||| S:328 E:331 ||| VB
discovered ||| S:331 E:341 ||| VBN
,  ||| S:341 E:343 ||| ,
the  ||| S:343 E:347 ||| DT
elucidation  ||| S:347 E:359 ||| NN
of  ||| S:359 E:362 ||| IN
the  ||| S:362 E:366 ||| DT
caspase  ||| S:366 E:374 ||| JJ
degradome  ||| S:374 E:384 ||| NN
will  ||| S:384 E:389 ||| MD
be  ||| S:389 E:392 ||| VB
an  ||| S:392 E:395 ||| DT
important  ||| S:395 E:405 ||| JJ
milestone  ||| S:405 E:415 ||| NN
in  ||| S:415 E:418 ||| IN
the  ||| S:418 E:422 ||| DT
study  ||| S:422 E:428 ||| NN
of  ||| S:428 E:431 ||| IN
these  ||| S:431 E:437 ||| DT
proteases  ||| S:437 E:447 ||| NN
in  ||| S:447 E:450 ||| IN
human  ||| S:450 E:456 ||| JJ
health  ||| S:456 E:463 ||| NN
and  ||| S:463 E:467 ||| CC
disease ||| S:467 E:474 ||| NN
.  ||| S:474 E:476 ||| .
Several  ||| S:476 E:484 ||| JJ
computational  ||| S:484 E:498 ||| JJ
methods  ||| S:498 E:506 ||| NNS
for  ||| S:506 E:510 ||| IN
predicting  ||| S:510 E:521 ||| VBG
caspase  ||| S:521 E:529 ||| JJ
cleavage  ||| S:529 E:538 ||| JJ
sites  ||| S:538 E:544 ||| NNS
have  ||| S:544 E:549 ||| VBP
been  ||| S:549 E:554 ||| VBN
developed  ||| S:554 E:564 ||| VBN
recently  ||| S:564 E:573 ||| RB
for  ||| S:573 E:577 ||| IN
identifying  ||| S:577 E:589 ||| VBG
potential  ||| S:589 E:599 ||| JJ
substrates ||| S:599 E:609 ||| NN
.  ||| S:609 E:611 ||| .
However ||| S:611 E:618 ||| RB
,  ||| S:618 E:620 ||| ,
as  ||| S:620 E:623 ||| IN
most  ||| S:623 E:628 ||| JJS
of  ||| S:628 E:631 ||| IN
these  ||| S:631 E:637 ||| DT
methods  ||| S:637 E:645 ||| NNS
are  ||| S:645 E:649 ||| VBP
based  ||| S:649 E:655 ||| VBN
primarily  ||| S:655 E:665 ||| RB
on  ||| S:665 E:668 ||| IN
the  ||| S:668 E:672 ||| DT
detection  ||| S:672 E:682 ||| NN
of  ||| S:682 E:685 ||| IN
the  ||| S:685 E:689 ||| DT
tetrapeptide  ||| S:689 E:702 ||| JJ
cleavage  ||| S:702 E:711 ||| JJ
sites  ||| S:711 E:717 ||| NNS
-  ||| S:717 E:719 ||| :
a  ||| S:719 E:721 ||| DT
factor  ||| S:721 E:728 ||| NN
necessary  ||| S:728 E:738 ||| JJ
but  ||| S:738 E:742 ||| CC
not  ||| S:742 E:746 ||| RB
sufficient  ||| S:746 E:757 ||| JJ
for  ||| S:757 E:761 ||| IN
predicting  ||| S:761 E:772 ||| VBG
in  ||| S:772 E:775 ||| IN
vivo  ||| S:775 E:780 ||| JJ
substrate  ||| S:780 E:790 ||| JJ
cleavage  ||| S:790 E:799 ||| NN
-  ||| S:799 E:801 ||| :
prediction  ||| S:801 E:812 ||| NN
outcomes  ||| S:812 E:821 ||| NNS
will  ||| S:821 E:826 ||| MD
inevitably  ||| S:826 E:837 ||| RB
include  ||| S:837 E:845 ||| VB
many  ||| S:845 E:850 ||| JJ
false  ||| S:850 E:856 ||| JJ
positives ||| S:856 E:865 ||| NN
.  ||| S:865 E:867 ||| .
In  ||| S:867 E:870 ||| IN
this  ||| S:870 E:875 ||| DT
paper ||| S:875 E:880 ||| NN
,  ||| S:880 E:882 ||| ,
we  ||| S:882 E:885 ||| PRP
show  ||| S:885 E:890 ||| VBP
that  ||| S:890 E:895 ||| IN
structural  ||| S:895 E:906 ||| JJ
factors  ||| S:906 E:914 ||| NNS
such  ||| S:914 E:919 ||| JJ
as  ||| S:919 E:922 ||| IN
the  ||| S:922 E:926 ||| DT
presence  ||| S:926 E:935 ||| NN
of  ||| S:935 E:938 ||| IN
disorder  ||| S:938 E:947 ||| NN
and  ||| S:947 E:951 ||| CC
solvent  ||| S:951 E:959 ||| JJ
exposure  ||| S:959 E:968 ||| NN
in  ||| S:968 E:971 ||| IN
the  ||| S:971 E:975 ||| DT
vicinity  ||| S:975 E:984 ||| NN
of  ||| S:984 E:987 ||| IN
the  ||| S:987 E:991 ||| DT
cleavage  ||| S:991 E:1000 ||| JJ
site  ||| S:1000 E:1005 ||| NN
are  ||| S:1005 E:1009 ||| VBP
important  ||| S:1009 E:1019 ||| JJ
and  ||| S:1019 E:1023 ||| CC
can  ||| S:1023 E:1027 ||| MD
be  ||| S:1027 E:1030 ||| VB
used  ||| S:1030 E:1035 ||| VBN
to  ||| S:1035 E:1038 ||| TO
enhance  ||| S:1038 E:1046 ||| VB
results  ||| S:1046 E:1054 ||| NNS
from  ||| S:1054 E:1059 ||| IN
cleavage  ||| S:1059 E:1068 ||| JJ
site  ||| S:1068 E:1073 ||| NN
prediction ||| S:1073 E:1083 ||| NN
.  ||| S:1083 E:1085 ||| .
We  ||| S:1085 E:1088 ||| PRP
constructed  ||| S:1088 E:1100 ||| VBD
a  ||| S:1100 E:1102 ||| DT
two-step  ||| S:1102 E:1111 ||| JJ
model  ||| S:1111 E:1117 ||| NN
incorporating  ||| S:1117 E:1131 ||| VBG
cleavage  ||| S:1131 E:1140 ||| JJ
site  ||| S:1140 E:1145 ||| NN
prediction  ||| S:1145 E:1156 ||| NN
and  ||| S:1156 E:1160 ||| CC
these  ||| S:1160 E:1166 ||| DT
factors  ||| S:1166 E:1174 ||| NNS
to  ||| S:1174 E:1177 ||| TO
predict  ||| S:1177 E:1185 ||| VB
caspase  ||| S:1185 E:1193 ||| JJ
substrates ||| S:1193 E:1203 ||| NN
.  ||| S:1203 E:1205 ||| .
Sequences  ||| S:1205 E:1215 ||| NNS
are  ||| S:1215 E:1219 ||| VBP
first  ||| S:1219 E:1225 ||| RB
predicted  ||| S:1225 E:1235 ||| VBN
for  ||| S:1235 E:1239 ||| IN
cleavage  ||| S:1239 E:1248 ||| JJ
sites  ||| S:1248 E:1254 ||| NNS
using  ||| S:1254 E:1260 ||| VBG
CASVM  ||| S:1260 E:1266 ||| NNP
or  ||| S:1266 E:1269 ||| CC
GraBCas ||| S:1269 E:1276 ||| JJ
.  ||| S:1276 E:1278 ||| .
Predicted  ||| S:1278 E:1288 ||| VBN
cleavage  ||| S:1288 E:1297 ||| JJ
sites  ||| S:1297 E:1303 ||| NNS
are  ||| S:1303 E:1307 ||| VBP
then  ||| S:1307 E:1312 ||| RB
scored ||| S:1312 E:1318 ||| VBN
,  ||| S:1318 E:1320 ||| ,
ranked  ||| S:1320 E:1327 ||| VBD
and  ||| S:1327 E:1331 ||| CC
filtered  ||| S:1331 E:1340 ||| NN
against  ||| S:1340 E:1348 ||| IN
a  ||| S:1348 E:1350 ||| DT
cut-off  ||| S:1350 E:1358 ||| JJ
based  ||| S:1358 E:1364 ||| VBN
on  ||| S:1364 E:1367 ||| IN
their  ||| S:1367 E:1373 ||| PRP$
propensities  ||| S:1373 E:1386 ||| NN
for  ||| S:1386 E:1390 ||| IN
locating  ||| S:1390 E:1399 ||| VBG
in  ||| S:1399 E:1402 ||| IN
disordered  ||| S:1402 E:1413 ||| NN
and  ||| S:1413 E:1417 ||| CC
solvent  ||| S:1417 E:1425 ||| JJ
exposed  ||| S:1425 E:1433 ||| JJ
regions ||| S:1433 E:1440 ||| NNS
.  ||| S:1440 E:1442 ||| .
Using  ||| S:1442 E:1448 ||| VBG
an  ||| S:1448 E:1451 ||| DT
independent  ||| S:1451 E:1463 ||| JJ
dataset  ||| S:1463 E:1471 ||| NN
of  ||| S:1471 E:1474 ||| IN
caspase  ||| S:1474 E:1482 ||| JJ
substrates ||| S:1482 E:1492 ||| NN
,  ||| S:1492 E:1494 ||| ,
the  ||| S:1494 E:1498 ||| DT
model  ||| S:1498 E:1504 ||| NN
was  ||| S:1504 E:1508 ||| VBD
shown  ||| S:1508 E:1514 ||| VBN
to  ||| S:1514 E:1517 ||| TO
achieve  ||| S:1517 E:1525 ||| VB
greater  ||| S:1525 E:1533 ||| JJR
positive  ||| S:1533 E:1542 ||| JJ
predictive  ||| S:1542 E:1553 ||| NN
values  ||| S:1553 E:1560 ||| VBZ
compared  ||| S:1560 E:1569 ||| VBN
to  ||| S:1569 E:1572 ||| TO
CASVM  ||| S:1572 E:1578 ||| NNP
or  ||| S:1578 E:1581 ||| CC
GraBCas  ||| S:1581 E:1589 ||| JJ
alone ||| S:1589 E:1594 ||| RB
,  ||| S:1594 E:1596 ||| ,
and  ||| S:1596 E:1600 ||| CC
was  ||| S:1600 E:1604 ||| VBD
able  ||| S:1604 E:1609 ||| JJ
to  ||| S:1609 E:1612 ||| TO
reduce  ||| S:1612 E:1619 ||| VB
the  ||| S:1619 E:1623 ||| DT
false  ||| S:1623 E:1629 ||| JJ
positives  ||| S:1629 E:1639 ||| JJ
pool  ||| S:1639 E:1644 ||| NN
by  ||| S:1644 E:1647 ||| IN
up  ||| S:1647 E:1650 ||| RB
to  ||| S:1650 E:1653 ||| TO
13 ||| S:1653 E:1655 ||| CD
%  ||| S:1655 E:1657 ||| NN
and  ||| S:1657 E:1661 ||| CC
53 ||| S:1661 E:1663 ||| CD
%  ||| S:1663 E:1665 ||| NN
respectively  ||| S:1665 E:1678 ||| RB
while  ||| S:1678 E:1684 ||| IN
retaining  ||| S:1684 E:1694 ||| VBG
all  ||| S:1694 E:1698 ||| DT
true  ||| S:1698 E:1703 ||| JJ
positives ||| S:1703 E:1712 ||| NN
.  ||| S:1712 E:1714 ||| .
We  ||| S:1714 E:1717 ||| PRP
applied  ||| S:1717 E:1725 ||| VBD
our  ||| S:1725 E:1729 ||| PRP$
prediction  ||| S:1729 E:1740 ||| NN
model  ||| S:1740 E:1746 ||| NN
on  ||| S:1746 E:1749 ||| IN
the  ||| S:1749 E:1753 ||| DT
family  ||| S:1753 E:1760 ||| NN
of  ||| S:1760 E:1763 ||| IN
receptor  ||| S:1763 E:1772 ||| FW
tyrosine  ||| S:1772 E:1781 ||| FW
kinases  ||| S:1781 E:1789 ||| FW
( ||| S:1789 E:1790 ||| -LRB-
RTKs ||| S:1790 E:1794 ||| NNP
)  ||| S:1794 E:1796 ||| -RRB-
and  ||| S:1796 E:1800 ||| CC
highlighted  ||| S:1800 E:1812 ||| VBD
several  ||| S:1812 E:1820 ||| JJ
members  ||| S:1820 E:1828 ||| NNS
as  ||| S:1828 E:1831 ||| IN
potential  ||| S:1831 E:1841 ||| JJ
caspase  ||| S:1841 E:1849 ||| JJ
targets ||| S:1849 E:1856 ||| NNS
.  ||| S:1856 E:1858 ||| .
The  ||| S:1858 E:1862 ||| DT
results  ||| S:1862 E:1870 ||| NNS
suggest  ||| S:1870 E:1878 ||| VBP
that  ||| S:1878 E:1883 ||| IN
RTKs  ||| S:1883 E:1888 ||| NNP
may  ||| S:1888 E:1892 ||| MD
be  ||| S:1892 E:1895 ||| VB
generally  ||| S:1895 E:1905 ||| RB
regulated  ||| S:1905 E:1915 ||| VBN
by  ||| S:1915 E:1918 ||| IN
caspase  ||| S:1918 E:1926 ||| JJ
cleavage  ||| S:1926 E:1935 ||| NN
and  ||| S:1935 E:1939 ||| CC
in  ||| S:1939 E:1942 ||| IN
some  ||| S:1942 E:1947 ||| DT
cases ||| S:1947 E:1952 ||| NNS
,  ||| S:1952 E:1954 ||| ,
promote  ||| S:1954 E:1962 ||| VB
the  ||| S:1962 E:1966 ||| DT
induction  ||| S:1966 E:1976 ||| NN
of  ||| S:1976 E:1979 ||| IN
apoptotic  ||| S:1979 E:1989 ||| JJ
cell  ||| S:1989 E:1994 ||| NN
death  ||| S:1994 E:2000 ||| NN
-  ||| S:2000 E:2002 ||| :
a  ||| S:2002 E:2004 ||| DT
function  ||| S:2004 E:2013 ||| NN
distinct  ||| S:2013 E:2022 ||| NN
from  ||| S:2022 E:2027 ||| IN
their  ||| S:2027 E:2033 ||| PRP$
role  ||| S:2033 E:2038 ||| NN
as  ||| S:2038 E:2041 ||| IN
transducers  ||| S:2041 E:2053 ||| NN
of  ||| S:2053 E:2056 ||| IN
survival  ||| S:2056 E:2065 ||| NN
and  ||| S:2065 E:2069 ||| CC
growth  ||| S:2069 E:2076 ||| NN
signals ||| S:2076 E:2083 ||| NNS
.  ||| S:2083 E:2085 ||| .
As  ||| S:2085 E:2088 ||| IN
a  ||| S:2088 E:2090 ||| DT
step  ||| S:2090 E:2095 ||| NN
towards  ||| S:2095 E:2103 ||| IN
the  ||| S:2103 E:2107 ||| DT
prediction  ||| S:2107 E:2118 ||| NN
of  ||| S:2118 E:2121 ||| IN
in  ||| S:2121 E:2124 ||| IN
vivo  ||| S:2124 E:2129 ||| JJ
caspase  ||| S:2129 E:2137 ||| JJ
substrates ||| S:2137 E:2147 ||| NN
,  ||| S:2147 E:2149 ||| ,
we  ||| S:2149 E:2152 ||| PRP
have  ||| S:2152 E:2157 ||| VBP
developed  ||| S:2157 E:2167 ||| VBN
an  ||| S:2167 E:2170 ||| DT
accurate  ||| S:2170 E:2179 ||| JJ
method  ||| S:2179 E:2186 ||| NN
incorporating  ||| S:2186 E:2200 ||| VBG
cleavage  ||| S:2200 E:2209 ||| JJ
site  ||| S:2209 E:2214 ||| NN
prediction  ||| S:2214 E:2225 ||| NN
and  ||| S:2225 E:2229 ||| CC
structural  ||| S:2229 E:2240 ||| JJ
factors ||| S:2240 E:2247 ||| NNS
.  ||| S:2247 E:2249 ||| .
The  ||| S:2249 E:2253 ||| DT
multi-factor  ||| S:2253 E:2266 ||| JJ
model  ||| S:2266 E:2272 ||| NN
augments  ||| S:2272 E:2281 ||| VBZ
existing  ||| S:2281 E:2290 ||| VBG
methods  ||| S:2290 E:2298 ||| NNS
and  ||| S:2298 E:2302 ||| CC
complements  ||| S:2302 E:2314 ||| VBZ
experimental  ||| S:2314 E:2327 ||| JJ
efforts  ||| S:2327 E:2335 ||| NNS
to  ||| S:2335 E:2338 ||| TO
define  ||| S:2338 E:2345 ||| VB
the  ||| S:2345 E:2349 ||| DT
caspase  ||| S:2349 E:2357 ||| JJ
degradome  ||| S:2357 E:2367 ||| NN
on  ||| S:2367 E:2370 ||| IN
the  ||| S:2370 E:2374 ||| DT
systems-wide  ||| S:2374 E:2387 ||| JJ
basis ||| S:2387 E:2392 ||| NN
.  ||| S:2392 E:2394 ||| .
